If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.



New possible target for rapid antidepressants found

Navitor molecule boosts mTORC1 activity, reduces depression symptoms in rats

by Emma Hiolski
November 20, 2017 | A version of this story appeared in Volume 95, Issue 47

This is the ribbon structure of the mechanistic target of rapamycin protein.
Credit: Shutterstock
The mechanistic target of rapamycin (mTOR) is an important node in many cell signaling pathways, and could be a new drug target for treating depression.

People with depression have to take currently available antidepressants for months before they start to get relief from their symptoms. But scientists are on the hunt for new, fast-acting antidepressants.

For example, ketamine can improve symptoms in a matter of hours, but comes with some undesirable side effects, such as hallucinations and out-of-body experiences. So researchers want to understand which cellular pathways ketamine turns on and off to find possible new antidepressant drug targets that don’t lead to acute psychiatric side effects.

Scientists at Yale University and Navitor Pharmaceuticals think they have a compound with potential. The molecule boosts activity of an important signaling hub in brain cells and rapidly alleviates symptoms of depression in rats. The team reported data on the molecule on Nov. 14 at the Society for Neuroscience annual meeting in Washington, D.C.

When ketamine binds to receptors on the surface of neurons, one of the downstream signaling protein complexes it activates is mTORC1. This protein complex is present in many cells in the body and regulates cell growth and metabolism in response to nutrient availability. One hallmark of depression is reduced mTORC1 activity in the brain, says Navitor CEO George P. Vlasuk, but finding a way to boost that activity has been difficult.

Navitor’s lead program focuses on developing new compounds to directly activate mTORC1 to treat a range of diseases. Their collaborators discovered a new way to turn up mTORC1 activity—a nutrient-sensing pathway mediated through a protein called sestrin2 (Science 2016, DOI: 10.1126/science.aab2674). The company then developed NV-5138, a small molecule that binds to sestrin2, which then releases its hold on mTORC1 and, as a result, activates the complex. Navitor’s patent for NV-5138 is still pending, so the structure has not yet been published.

Ronald S. Duman, of Yale University, led the effort to test the new compound as an antidepressant. In rats with depressionlike symptoms, an oral dose of NV-5138 rapidly penetrated the brain and, within one hour, activated mTORC1 in the prefrontal cortex, a brain region heavily affected in depression.

And, similar to ketamine, NV-5138 boosted the density and strength of connections between neurons in the prefrontal cortex. The small molecule relieved some symptoms of depression in rats, such as a lack of interest in a treat (sugar water), and the effects of a single dose lasted up to 7 days despite a short half-life of several hours.

The main novelty with NV-5138, according to Duman, is that it acts downstream of the receptors that ketamine binds to on nerve cells. This may circumvent some of the negative side effects caused by ketamine, he says.

“It sounds very promising,” comments Joseph R. Moskal, of Northwestern University and chief scientific officer at the biopharmaceutical company Aptinyx. He says that although the data are preliminary, the logic behind this target makes sense.

Lisa Monteggia, a neuroscientist at the University of Texas Southwestern Medical Center, points out that mTORC1 interacts with many cellular processes, so directly activating it could still trigger side effects.

Vlasuk agrees. “This is the first small molecule direct activator of mTORC1 that’s been described,” he says. “We want to know as much about it as we can.” The next step for Navitor scientists is to assess NV-5138’s safety and efficacy in humans, he says. The company plans to begin phase I trials in the first half of 2018.

This article has been translated into Spanish by and can be found here.


This article has been sent to the following recipient:

Chemistry matters. Join us to get the news you need.